[Bio Story]①"RPT Can't Be Sold with Just a Good Drug—Strength Lies in Having All Three Pillars"
Jae-yoon Ji, CEO of FutureChem, Interview ①
"If you change the target, it becomes a different cancer therapy"
"The ligand platform is the real weapon"
"The radiopharmaceutical (RPT) business is not something that can succeed with just a single good drug. You need three pillars in place: new drugs, a high-quality GMP production facility, and automated synthesis equipment. Only with all three can you truly establish such a business, and in Korea, FutureChem is the only company that possesses all three pillars."
Jae-yoon Ji, CEO of FutureChem, expressed his confidence in an interview with The Asia Business Daily on August 20, stating, "Korea can have leading competitiveness in the RPT market," and explaining as such.
Jae-yoon Ji, CEO of FutureChem, is being interviewed by The Asia Business Daily at the headquarters in Seongdong-gu, Seoul. Photo by Jung-yeon Park
View original imageThe RPT market has recently emerged as a new battleground for anticancer drugs. This field, which selectively delivers radioactive isotopes to cancer cells to achieve diagnosis and treatment simultaneously, has become the target of mergers and acquisitions (M&A) by major global pharmaceutical companies such as Eli Lilly, Bristol Myers Squibb (BMS), and AstraZeneca in recent years. On August 3, France's Curium agreed to acquire U.S.-based Lantheus—known for its prostate cancer diagnostic agent 'Pylarify'—for up to 8 billion dollars (approximately 11 trillion won). Novartis, the early mover in this market, generated 2.8 billion dollars (about 4 trillion won) last year with just two products: Pluvicto and Lutathera.
The market is also expanding rapidly in Korea. Large conglomerates, including SK Biopharmaceuticals, are identifying RPT as a next-generation growth driver and entering the market. Among these, FutureChem is regarded as the most advanced player domestically. In May, the company launched ProstaView (FC303), the 43rd locally developed new drug, as a prostate cancer diagnostic agent, and is preparing to announce phase 2a clinical trial results for its prostate cancer treatment FC705 in the United States in the fourth quarter of this year.
CEO Ji repeatedly emphasized the 'three pillars' because the RPT business model does not allow for the export of final products. The fluorine-18 isotope used in diagnostic radiopharmaceuticals loses half its radioactivity every two hours and essentially becomes ineffective after ten hours post-synthesis. Therefore, production facilities and automated synthesis equipment must be located near the facilities where the drugs are used, making it necessary for sales structures to be local.
The core issue is that it is challenging for any single company to have all three pillars in place. Even if you develop a good drug, if you lack production facilities or automated synthesis equipment, you must procure these from other companies. Since a small number of companies dominate the market, the bargaining power naturally lies with the seller. CEO Ji said, "The companies hold all the power, so negotiations are impossible. Chemists do not know machines, and those running the machines do not know chemistry, so even if we request the devices we need, there was no one willing to make them."
Another competitive edge for FutureChem is its possession of both diagnostic and therapeutic agents. ProstaView and the clinical-stage FC705 are based on the same ligand. Ligands are compounds that specifically bind only to certain proteins on the surface of cancer cells and act as carriers for radioactive isotopes. When you attach an isotope for imaging, it becomes a diagnostic agent; when you attach an isotope that can destroy cancer cells, it becomes a therapeutic agent. This creates a closed-loop system in which diagnostics confirm target expression, treatment is administered, and response is tracked using the same mechanism.
Ji added, "The tumor-to-background ratio (TBR), the difference in signal between tumors and surrounding tissues, exceeds twice that of competing products. There are doctors who, after viewing our imaging, say that 'the door has opened.'"
If You Change a Single Component, It Becomes Another Cancer Therapy
What CEO Ji sees as the company's ultimate competitive strength is that this structure is not limited to a single cancer target. By switching out the ligand that binds to cancer cell surface proteins, the same platform can be applied to different types of cancer. He stated, "If you replace the compound targeting prostate cancer with one tailored for another target, it can directly become a therapy for pancreatic cancer or triple-negative breast cancer. It typically takes ten years to discover such compounds, but we possess a platform that can achieve this." FutureChem is collaborating with Seoul National University Hospital and Korea Advanced Institute of Science and Technology (KAIST) researchers to discover new targets using artificial intelligence (AI).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company's wide selection of radioactive isotopes is another key strength. In the industry, beta-emitting isotopes such as Lutetium-177 and Terbium-161 compete alongside alpha-emitting isotopes like Actinium-225 and Lead-212, but no clear winner has yet been established. Ji said, "No one knows which isotope will become the standard. Our compound can accommodate all five types, so if we can address supply or cost issues, we will be prepared for any direction the market takes."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.